PATENT CLAIM ANALYSIS

Application Number: 16165202
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["424", "450000"]

Abstract:
The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Claim (Index 26):
The method according to  claim 24 , wherein the sphingolipids comprise sphingomyelin.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 2.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14420654', '15216416', '15768352', '16126799', '13581274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7089172573573943
- 35 USC 102 Novelty (BERT): 0.5552472810895176
- Combined Prediction Score: 0.6935502597306067
- Mean Citation Score: 273.173486
- Max Citation Score: 444.79718
- Similarity Product: 299.57980939086565

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test